as of 02-19-2026 3:53pm EST
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
| Founded: | 2004 | Country: | US |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 14.0B | IPO Year: | 2015 |
| Target Price: | $350.94 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.32 | EPS Growth: | -84.48 |
| 52 Week Low/High: | $221.26 - $362.41 | Next Earning Date: | 04-15-2026 |
| Revenue: | $1,194,615,000 | Revenue Growth: | 12.86% |
| Revenue Growth (this year): | 17.03% | Revenue Growth (next year): | 14.38% |
| P/E Ratio: | 102.83 | Index: | N/A |
| Free Cash Flow: | 147.3M | FCF Growth: | +13.74% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Director
Avg Cost/Share
$312.64
Shares
186
Total Value
$58,151.04
Owned After
8,230
SEC Form 4
Director
Avg Cost/Share
$310.72
Shares
186
Total Value
$57,793.92
Owned After
0
SEC Form 4
Director
Avg Cost/Share
$308.72
Shares
15,000
Total Value
$4,632,292.11
Owned After
271,432
EVP, Gen. Counsel & Secretary
Avg Cost/Share
$300.13
Shares
300
Total Value
$90,039.00
Owned After
63,836
SEC Form 4
Director
Avg Cost/Share
$292.98
Shares
100
Total Value
$29,298.00
Owned After
8,230
SEC Form 4
EVP, Gen. Counsel & Secretary
Avg Cost/Share
$295.29
Shares
600
Total Value
$176,966.11
Owned After
63,836
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Grewal Harpreet | PEN | Director | Jan 6, 2026 | Sell | $312.64 | 186 | $58,151.04 | 8,230 | |
| Wilder Thomas | PEN | Director | Jan 2, 2026 | Sell | $310.72 | 186 | $57,793.92 | 0 | |
| Bose Arani | PEN | Director | Dec 11, 2025 | Sell | $308.72 | 15,000 | $4,632,292.11 | 271,432 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Dec 5, 2025 | Sell | $300.13 | 300 | $90,039.00 | 63,836 | |
| Grewal Harpreet | PEN | Director | Dec 2, 2025 | Sell | $292.98 | 100 | $29,298.00 | 8,230 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Dec 1, 2025 | Sell | $295.29 | 600 | $176,966.11 | 63,836 |
See how PEN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PEN Penumbra Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.